Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) has shared an announcement.
Rhythm Biosciences has applied to the ASX for quotation of 90,842 new fully paid ordinary shares. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly increasing the company’s listed share capital and slightly broadening its equity base for investors.
The issuance of these shares reflects the uptake of previously granted securities and may provide incremental liquidity in Rhythm Biosciences’ stock on the market. While the scale of this quotation is limited, it signals ongoing engagement with capital markets and may marginally adjust ownership positions among existing shareholders.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. is an ASX-listed biotechnology company focused on developing diagnostic technologies in the healthcare sector. The company’s primary activities center on creating and commercializing bioscience-based solutions, targeting medical markets that rely on advanced testing and screening tools.
Average Trading Volume: 1,059,710
Technical Sentiment Signal: Buy
Current Market Cap: A$60.85M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.